Friday, July 10, 2026

Drug profile · INN

pegfilgrastim-jmdb

pegfilgrastim-jmdb (FULPHILA) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — pegfilgrastim-jmdb
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

pegfilgrastim-jmdb (FULPHILA) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN pegfilgrastim-jmdb
Brand FULPHILA
Mechanism Granulocyte colony stimulating factor receptor agonist
Target Granulocyte colony-stimulating factor receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Granulocyte colony stimulating factor receptor agonist

Primary target: Granulocyte colony-stimulating factor receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. filgrastim Antineoplastic and immunomodulating agents (L03)
  2. lipegfilgrastim Antineoplastic and immunomodulating agents (L03)
  3. pegfilgrastim-cbqv Granulocyte colony stimulating factor receptor agonist
  4. efbemalenograstim alfa-vuxw Granulocyte colony stimulating factor receptor agonist
  5. eflapegrastim-xnst Granulocyte colony stimulating factor receptor agonist
  6. filgrastim-aafi Granulocyte colony stimulating factor receptor agonist

Frequently asked questions

What is pegfilgrastim-jmdb?

pegfilgrastim-jmdb (FULPHILA) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for pegfilgrastim-jmdb?

FULPHILA is a marketed brand name for pegfilgrastim-jmdb. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of pegfilgrastim-jmdb?

pegfilgrastim-jmdb has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.